비침습적 산전 검사 시장 예측(-2030년) : 제품, 방법, 임신 기간, 기술, 용도, 최종 사용자 및 지역별 세계 분석

According to Stratistics MRC, the Global Non-Invasive Prenatal Testing (NIPT) Market is accounted for $4.2 billion in 2023 and is expected to reach $9.1 billion by 2030 growing at a CAGR of 11.6% during the forecast period. A DNA-based blood test called non-invasive prenatal testing is used to determine the growing foetus's risk of genetic diseases. A sort of screening test called Non-Invasive Prenatal Testing (NIPT) is used to identify specific genetic disorders in the growing fetus during pregnancy. NIPT is a non-invasive treatment that requires a mother's simple blood test, as opposed to invasive procedures like amniocentesis or chorionic villus sampling (CVS).

According to Eurostat, in 2017, around 45% of women in the European Union who gave birth to their first child belonged to the average age group of 29.1 years. Also, in the same year, around 78,275 births of first children were reported in women aged more than 40 years.

Market Dynamics:

Driver:

Need for accurate and sophisticated screening

The development of extremely sophisticated screening methods that are highly sensitive and accurate in the early detection of genetic abnormalities in newborns is a continuing priority for a number of businesses. Manufacturers are placing a lot of emphasis on the creation of cutting-edge noninvasive prenatal diagnostics and forming strategic alliances and collaborations to boost their market share. These are the factors influencing the growth of the market.

Restraint:

Limited availability of counseling

Even while the NIPT offers useful information, people may not always have easy access to enough counseling and assistance to fully comprehend the consequences of the results and make decisions. There may be ethical and legal issues with using NIPT data in some areas due to a lack of defined laws around its usage and interpretation. These are the aspects affecting the market's expansion.

Opportunity:

High risk of chromosomal abnormalities with increasing maternal age

Growing older mothers are more likely to have high blood pressure, limited fertility, miscarriages, stillbirths, and maternal death, among other health problems. Furthermore, the risk of genetic disorders in neonates might increase with maternal age due to improper chromosomal division. Therefore, it is anticipated that the market would be driven by the rising frequency of chromosomal abnormalities along with the aging of mothers.

Threat:

High cost of tests

Growing populations in emerging nations would be hampered by a lack of knowledge about the hazards associated with genetic disorders. However, some other issues that can restrict market expansion include reduced per capita healthcare spending and inadequate test reimbursement rules. The adoption of these tests will be restricted by their high cost, which makes them comparatively unaffordable in many developing nations.

COVID-19 Impact:

Prenatal care was among the regular medical treatments that were difficult to obtain during the pandemic's height. There were some visits that were cancelled or done virtually, which had an impact on the regularity of NIPT and other prenatal tests. In order to handle COVID-19 cases, healthcare resources were reallocated, which could have had an impact on the accessibility of NIPT testing or lengthened wait times for those in need of these services.

The ultrasound detection segment is expected to be the largest during the forecast period

The ultrasound detection segment is expected to be the largest during the forecast period. This is the method that is most favored and used for the ultrasound machine is utilized in this technique. Using a probe, sound pulses with frequency between one and five megahertz are injected into the body during the test. In addition, the probe serves as a receiver for sound waves reflected off tissue surfaces.

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period

The diagnostic laboratories segment is expected to have the highest CAGR during the forecast period. The testing environment where the test is conducted is a diagnostic laboratory. Various testing services are offered by the laboratories based on the needs of the patients. Because there are so many diagnostic labs and centers that offer testing services and goods, the diagnostic laboratories category is the largest.

Region with largest share:

North America is projected to hold the largest market share during the forecast period. The adoption and demand for testing in this region is expected to rise due to the high prevalence of preterm births, high rate of maternal mortality, and increased occurrences of chromosomal abnormalities. Numerous studies provide light on the efficacy of raising awareness of prenatal care. In addition, the market is expanding due to high diagnosis rates, increased public adoption and awareness, and the release of new, more technologically sophisticated tests.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period owing to the rising maternal age, which contributes to the growing incidence of chromosomal aneuploidies in babies, leading to a rise in the potential customer base. The technical integration of NGS techniques, significant advancements in China and Japan, and enhanced healthcare infrastructure are anticipated to propel market expansion.

Key players in the market:

Some of the key players in Non-Invasive Prenatal Testing (NIPT) market include Centogene N.V., Natera, Inc., MedGenome Labs Ltd., Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH, Myriad Women's Health, Inc., F. Hoffmann-La Roche Ltd., Progenity, Inc., Illumina, Inc., Genesis Genetics, Qiagen, Laboratory Corp. of America Holdings, Quest Diagnostics, Inc., PerkinElmer Inc., and Yourgene Health

Key Developments:

In August 2022, Natera Inc. filed a pre-submission to the Food and Drug Administration (FDA) for its panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process. The company filed its pre-submission in June 2022 for fetal chromosomal aneuploidies and 22q11.2 deletion syndrome.

In July 2022, Genetic Technologies Limited acquired EasyDNA as the company expanded the availability on its websites of Carrier Testing and Non-Invasive Prenatal Tests (NIPT) in Europe.

Products Covered:

• Disposables
• Ultrasound Devices
• Assay Kits & Reagents
• Polymerase Chain Reaction Instruments
• Next-Generation Sequencing Systems
• Microarrays
• Other Products

Methods Covered:

• Ultrasound Detection
• Biochemical Screening Tests
• Cell-Free DNA in Maternal Plasma Tests

Gestation Periods Covered:

• 0-12 Weeks
• 13-24 Weeks
• 25-36 Weeks

Technologies Covered:

• Next Generation Sequencing (NGS)
• Microarray
• Rolling Circular Amplification
• Other Technologies

Applications Covered:

• Microdeletion Syndrome
• Trisomy
• Other Applications

End Users Covered:

• Diagnostic Laboratories
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Non Invasive Prenatal Testing (NIPT) Market, By Product

• 5.1 Introduction
• 5.2 Disposables
• 5.3 Ultrasound Devices
• 5.4 Assay Kits & Reagents
• 5.5 Polymerase Chain Reaction Instruments
• 5.6 Next-Generation Sequencing Systems
• 5.7 Microarrays
• 5.8 Other Products

6 Global Non Invasive Prenatal Testing (NIPT) Market, By Method

• 6.1 Introduction
• 6.2 Ultrasound Detection
• 6.3 Biochemical Screening Tests
• 6.4 Cell-Free DNA in Maternal Plasma Tests

7 Global Non Invasive Prenatal Testing (NIPT) Market, By Gestation Period

• 7.1 Introduction
• 7.2 0-12 Weeks
• 7.3 13-24 Weeks
• 7.4 25-36 Weeks

8 Global Non Invasive Prenatal Testing (NIPT) Market, By Technology

• 8.1 Introduction
• 8.2 Next Generation Sequencing (NGS)
• 8.3 Microarray
• 8.4 Rolling Circular Amplification
• 8.5 Other Technologies

9 Global Non Invasive Prenatal Testing (NIPT) Market, By Application

• 9.1 Introduction
• 9.2 Microdeletion Syndrome
• 9.3 Trisomy
• 9.4 Other Applications

10 Global Non Invasive Prenatal Testing (NIPT) Market, By End User

• 10.1 Introduction
• 10.2 Diagnostic Laboratories
• 10.3 Hospitals
• 10.4 Other End Users

11 Global Non Invasive Prenatal Testing (NIPT) Market, By Geography

• 11.1 Introduction
• 11.2 North America
  • 11.2.1 US
  • 11.2.2 Canada
  • 11.2.3 Mexico
• 11.3 Europe
  • 11.3.1 Germany
  • 11.3.2 UK
  • 11.3.3 Italy
  • 11.3.4 France
  • 11.3.5 Spain
  • 11.3.6 Rest of Europe
• 11.4 Asia Pacific
  • 11.4.1 Japan
  • 11.4.2 China
  • 11.4.3 India
  • 11.4.4 Australia
  • 11.4.5 New Zealand
  • 11.4.6 South Korea
  • 11.4.7 Rest of Asia Pacific
• 11.5 South America
  • 11.5.1 Argentina
  • 11.5.2 Brazil
  • 11.5.3 Chile
  • 11.5.4 Rest of South America
• 11.6 Middle East & Africa
  • 11.6.1 Saudi Arabia
  • 11.6.2 UAE
  • 11.6.3 Qatar
  • 11.6.4 South Africa
  • 11.6.5 Rest of Middle East & Africa

12 Key Developments

• 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 12.2 Acquisitions & Mergers
• 12.3 New Product Launch
• 12.4 Expansions
• 12.5 Other Key Strategies

13 Company Profiling

13.1 Centogene N.V.

• 13.2 Natera, Inc.
• 13.3 MedGenome Labs Ltd.
• 13.4 Eurofins LifeCodeNon Invasive Prenatal Testing (NIPT) GmbH
• 13.5 F. Hoffmann-La Roche Ltd.
• 13.6 Progenity, Inc.
• 13.7 Illumina, Inc.
• 13.8 Genesis Genetics
• 13.9 Qiagen
• 13.10 Laboratory Corp. of America Holdings
• 13.11 Quest Diagnostics, Inc.
• 13.12 PerkinElmer Inc.
• 13.13 Your gene Health
• 13.14 Perkinelmer, Inc.